Detail page

Knowledge Web

Person

Joachim Boos

Onkologe

Name	Joachim Boos
Place	Deutschland
Academic degree	Prof. Dr. med.
Profession	Onkologe (characteristic profession)
Variant	J. Boos
Related	Westfälische Wilhelms-Universität Münster
Record type	Person
GND-Identifier	111133270
Record ID	111133270
Involved in show all PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia Treated within the AIEOP-BFM ALL 2009 Trial: Population Pharmacokinetics and Drug Exposure Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring Hypersensitivity reactions to native E. coli L-asparaginase in children with acute lymphoblastic leukemia treated in Trial ALL-BFM 2000: impact of treatment schedule and type of glucocorticoid in induction Neue AWMF-S2k-Leitlinie Bewegungsförderung und Bewegungstherapie in der pädiatrischen Onkologie Bedeutung des Fahrradfahrens in der Kinderonkologie : Analyse der Fahrradnutzung in der pädiatrischen Hämatologie und Onkologie hinsichtlich der körperlichen Aktivität, psychosozialer und sozialrechtlicher Faktoren Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data Adverse events during supervised exercise interventions in pediatric oncology - a nationwide survey Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007 Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study Effektivität einer Kombination von Telomerasehemmung und Chemotherapie beim Ewing Sarkom Sarcoma on Ski: Individual Skiing Concepts Enable Autonomous Skiing After Multimodal Therapy for Pediatric Muscular-Skeletal Tumors Auswirkung von Dichloracetat auf die Zytotoxizität konventioneller Chemotherapeutika gegen pädiatrische neoplastische Zelllinien Objectively measured versus self-reported physical activity in children and adolescents with cancer Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial Towards a Model-Based Dose Recommendation for Doxorubicin in Children Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors Improved 6-year overall survival in AT/RT - results of the registry study rhabdoid 2007 Zwischen Anspruch und Wirklichkeit - Aufklärung und Patientenautonomie in Therapieoptimierungsstudien am Beispiel der Studie AIEOP-BFM ALL 2009 Untersuchung zur in-vitro-Toxizität eines Inhibitors der Aurorakinase A B, von Vincristin und Paclitaxel an einem Panel von 18 ausgewählten pädiatrischen Tumor-Zelllinien Feasibility of Intensive Multimodal Therapy in Infants Affected by Rhabdoid Tumors – Experience of the EU-RHAB registry In-vitro-Effekte von SAHA, Tyrphostin AG 1478 und Carmustin an einem Panel von 18 pädiatrisch-onkologischen Zelllinien Etoposid im Neuroblastomprotokoll Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children Carboplatin Dosing in Children: Calculation by Different Formulae Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patients Forschung mit Minderjährigen : medizinische, rechtliche und ethische Aspekte Pharmakokinetische Aspekte der oralen Applikation von Etoposid Nutzen und Schaden aus klinischer Forschung am Menschen : Abwägung, Equipoise und normative Grundlagen. Mit der Dokumentation der 25. Jahresversammlung des Arbeitskreises Medizinischer Ethik-Kommissionen in der Bundesrepublik Deutschland am 9. und 10. November 2007 im Haus der Bundesärztekammer in Berlin Implementing Good Clinical Practice in Two Noncommercial Phase II Studies in Children with Cancer Monitoring of Mycophenolic Acid in the Plasma of Transplant Patients by Capillary Electrophoresis Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications Population pharmacokinetics of oral busulfan in children Effektive Rezidivtherapie der akuten myeloischen Leukämie im Kindesalter mit liposomalem Daunorubicin und Cytarabin Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma Determination of mycophenolic acid and its glucuronide conjugate in human plasma by capillary electrophoresis The stability of doxorubicin and ldarubicin in plasma and whole blood Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide Pharmacokinetics of trofosfamide and its dechloroethylated metabolites Fakten zur Sedierung bei Kindern Intrazelluläre Retention von Cytarabin-Triphosphat (Ara-CTP) in Blasten von Kindern mit akuter lymphoblastischer Leukämie : Korrelation zu klinischen Verlaufsparametern Klinisch-pharmakologische Untersuchungen der Zytostatika Etoposid und Cytarabin sowie ihrer Kombination im Rahmen der pädiatrisch-onkologischen Therapieprotokolle : 30 Tabellen Untersuchungen zur Entwicklung Vitamin-K-abhängiger Gerinnungsparameter in der ersten Lebenswoche unter besonderer Berücksichtigung von PIVKA II : ist durch e. einmalige orale Vitamin-K-Gabe ihre Beeinflussung möglich?

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Joachim Boos

PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia Treated within the AIEOP-BFM ALL 2009 Trial: Population Pharmacokinetics and Drug Exposure

Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring

Hypersensitivity reactions to native E. coli L-asparaginase in children with acute lymphoblastic leukemia treated in Trial ALL-BFM 2000: impact of treatment schedule and type of glucocorticoid in induction

Neue AWMF-S2k-Leitlinie Bewegungsförderung und Bewegungstherapie in der pädiatrischen Onkologie

Bedeutung des Fahrradfahrens in der Kinderonkologie : Analyse der Fahrradnutzung in der pädiatrischen Hämatologie und Onkologie hinsichtlich der körperlichen Aktivität, psychosozialer und sozialrechtlicher Faktoren

Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach

Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data

Adverse events during supervised exercise interventions in pediatric oncology - a nationwide survey

Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring

Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure

Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007

Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study

Effektivität einer Kombination von Telomerasehemmung und Chemotherapie beim Ewing Sarkom

Sarcoma on Ski: Individual Skiing Concepts Enable Autonomous Skiing After Multimodal Therapy for Pediatric Muscular-Skeletal Tumors

Auswirkung von Dichloracetat auf die Zytotoxizität konventioneller Chemotherapeutika gegen pädiatrische neoplastische Zelllinien

Objectively measured versus self-reported physical activity in children and adolescents with cancer

Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial

Towards a Model-Based Dose Recommendation for Doxorubicin in Children

Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors

Improved 6-year overall survival in AT/RT - results of the registry study rhabdoid 2007

Zwischen Anspruch und Wirklichkeit - Aufklärung und Patientenautonomie in Therapieoptimierungsstudien am Beispiel der Studie AIEOP-BFM ALL 2009

Untersuchung zur in-vitro-Toxizität eines Inhibitors der Aurorakinase A B, von Vincristin und Paclitaxel an einem Panel von 18 ausgewählten pädiatrischen Tumor-Zelllinien

Feasibility of Intensive Multimodal Therapy in Infants Affected by Rhabdoid Tumors – Experience of the EU-RHAB registry

In-vitro-Effekte von SAHA, Tyrphostin AG 1478 und Carmustin an einem Panel von 18 pädiatrisch-onkologischen Zelllinien

Etoposid im Neuroblastomprotokoll

Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children

Carboplatin Dosing in Children: Calculation by Different Formulae

Early decrements in bone density after completion of neoadjuvant chemotherapy in pediatric bone sarcoma patients

Forschung mit Minderjährigen : medizinische, rechtliche und ethische Aspekte

Pharmakokinetische Aspekte der oralen Applikation von Etoposid

Implementing Good Clinical Practice in Two Noncommercial Phase II Studies in Children with Cancer

Monitoring of Mycophenolic Acid in the Plasma of Transplant Patients by Capillary Electrophoresis

Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay

Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery

Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis

Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications

Population pharmacokinetics of oral busulfan in children

Effektive Rezidivtherapie der akuten myeloischen Leukämie im Kindesalter mit liposomalem Daunorubicin und Cytarabin

Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma

Determination of mycophenolic acid and its glucuronide conjugate in human plasma by capillary electrophoresis

The stability of doxorubicin and ldarubicin in plasma and whole blood

Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide

Pharmacokinetics of trofosfamide and its dechloroethylated metabolites

Fakten zur Sedierung bei Kindern

Intrazelluläre Retention von Cytarabin-Triphosphat (Ara-CTP) in Blasten von Kindern mit akuter lymphoblastischer Leukämie : Korrelation zu klinischen Verlaufsparametern

Klinisch-pharmakologische Untersuchungen der Zytostatika Etoposid und Cytarabin sowie ihrer Kombination im Rahmen der pädiatrisch-onkologischen Therapieprotokolle : 30 Tabellen

Untersuchungen zur Entwicklung Vitamin-K-abhängiger Gerinnungsparameter in der ersten Lebenswoche unter besonderer Berücksichtigung von PIVKA II : ist durch e. einmalige orale Vitamin-K-Gabe ihre Beeinflussung möglich?